In addition, some drugs that target metabolic risk factors, such as glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors, can be given on a case-by-case basis and may benefit both the liver and kidneys in patients with MAFLD and CKD. The gene discussed is SLC5A2; the disease is chronic kidney disease.